董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jayson Dallas | 男 | Director | 57 | 未披露 | 未持股 | 2025-11-10 |
| Amit D. Munshi | 男 | Director | 57 | 未披露 | 未持股 | 2025-11-10 |
| Hans T. Schambye | 男 | President, Chief Executive Officer and Director | 60 | 47.90万美元 | 未持股 | 2025-11-10 |
| Chris Cain | 男 | Director | 41 | 未披露 | 未持股 | 2025-11-10 |
| Peter Harwin | 男 | Director | 39 | 未披露 | 未持股 | 2025-11-10 |
| Peter Harwin | 男 | Director | 39 | 未披露 | 未持股 | 2025-11-10 |
| Chris Cain | 男 | Director | 41 | 未披露 | 未持股 | 2025-11-10 |
| Julianne Bruno | 女 | Director | 40 | 未披露 | 未持股 | 2025-11-10 |
| Carl Goldfischer | 男 | Director and Chair of the Board | 66 | 未披露 | 未持股 | 2025-11-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hans T. Schambye | 男 | President, Chief Executive Officer and Director | 60 | 47.90万美元 | 未持股 | 2025-11-10 |
| Matthew Kronmiller | 男 | Executive Vice President of Strategy and Chief Business Officer | 38 | 未披露 | 未持股 | 2025-11-10 |
| Lori Firmani | 女 | Interim Chief Financial Officer | 52 | 未披露 | 未持股 | 2025-11-10 |
| Garrett Winslow | 男 | General Counsel | 46 | 未披露 | 未持股 | 2025-11-10 |
董事简历
中英对照 | 中文 | 英文- Jayson Dallas
-
Jayson Dallas。自2015年8月起担任首席商务官和高级副总裁。在加入Ultragenyx之前，Dallas博士于2012年7月至2015年7月在英国担任Roche（一家医疗公司）的总经理。 在此之前，他在Genentech（一家制药公司）担任两个不同的职位，从2010年5月至2012年6月担任全球肿瘤学推出卓越和生物仿制的战略主管，以及免疫学和眼科全球产品战略主管。在加入Genentech之前， Dallas先生在美国 Novartis 和 Pharmacia 工作，之前在瑞士Roche工作。Dallas 博士拥有南非约翰内斯堡University of the Witwatersrand的工商管理硕士学位，以及英国 Ashridge Business School工商管理硕士学位。
Jayson Dallas, M.D. has served as our Executive Vice President since January 2016 and our Chief Commercial Officer since August 2015. Between August 2015 and January 2016 he served as our Senior Vice President. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a healthcare company, in the United Kingdom from July 2012 to July 2015. Prior to this, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology from May 2010 to June 2012. Prior to joining Genentech, Dr. Dallas worked at Novartis and Pharmacia in the U.S. and previously at Roche in Switzerland. Dr. Dallas has also served as a board member of Arena Pharmaceuticals Inc. since February 2017. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom. - Jayson Dallas。自2015年8月起担任首席商务官和高级副总裁。在加入Ultragenyx之前，Dallas博士于2012年7月至2015年7月在英国担任Roche（一家医疗公司）的总经理。 在此之前，他在Genentech（一家制药公司）担任两个不同的职位，从2010年5月至2012年6月担任全球肿瘤学推出卓越和生物仿制的战略主管，以及免疫学和眼科全球产品战略主管。在加入Genentech之前， Dallas先生在美国 Novartis 和 Pharmacia 工作，之前在瑞士Roche工作。Dallas 博士拥有南非约翰内斯堡University of the Witwatersrand的工商管理硕士学位，以及英国 Ashridge Business School工商管理硕士学位。
- Jayson Dallas, M.D. has served as our Executive Vice President since January 2016 and our Chief Commercial Officer since August 2015. Between August 2015 and January 2016 he served as our Senior Vice President. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a healthcare company, in the United Kingdom from July 2012 to July 2015. Prior to this, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology from May 2010 to June 2012. Prior to joining Genentech, Dr. Dallas worked at Novartis and Pharmacia in the U.S. and previously at Roche in Switzerland. Dr. Dallas has also served as a board member of Arena Pharmaceuticals Inc. since February 2017. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.
- Amit D. Munshi
-
AmitD.Munshi自2020年起担任我们的董事会主席。Munshi先生目前自2016年5月起担任生物制药公司ArenaPharmaceuticals，Inc.的总裁兼首席执行官。在此之前，Munshi先生于2012年5月至2016年5月担任生物制药公司EPIRUSBiopharmaceuticals，Inc.的总裁兼首席执行官。他曾担任Percivia公司（生物技术公司，后被JNJ公司收购）的总裁兼首席执行官（2011年4月至2012年5月）。在其职业生涯早期，Munshi先生于2005年8月至2011年1月共同创立并担任KytheraBiopharmaceuticals，Inc.（后被AGN收购）的首席商务官，并于1997年9月至2005年1月在安进公司担任多个领导职位，包括肾脏学欧洲总经理。Munshi先生还于2014年8月共同创立了Oxeia Biopharmaceuticals，Inc.，这是一家临床阶段的生物技术公司。Munshi先生目前在Pulmatrix，Inc.董事会任职。纳斯达克股票代码:PULM。2016年7月，Epirus向美国马萨诸塞州破产法院提交了自愿的第7章请愿书。Munshi先生拥有加州大学河滨分校（University of California，Riverside）的经济学学士学位和历史学学士学位，以及克莱蒙特研究生大学彼得·德鲁克管理学院（Peter F.Drucker School of Management at Claremont Graduate University）的工商管理硕士学位。
Amit D. Munshi,served as President, Chief Executive Officer and board member of ORNA Therapeutics from May 2024 until March 2025 and, prior to that he served in the same roles at ReNAgade Therapeutics, a private biotechnology company that was acquired by ORNA Therapeutics, from May 2023 until May 2024. Prior to that, Mr. Munshi served as President, Chief Executive Officer and a director of Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company, from May 2016 until its acquisition by Pfizer Inc. in March 2022. Mr. Munshi served as President and Chief Executive Officer and a director of Epirus Biopharmaceuticals, Inc. ("Epirus") (Nasdaq: EPRS), a biopharmaceutical company, from May 2012 to May 2016. He served as President and Chief Executive Officer of Percivia LLC, a biotechnology company later acquired by Johnson & Johnson, from April 2011 to May 2012. Earlier in his career, Mr. Munshi co-founded and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., later acquired by Allergan plc, from August 2005 to January 2011, and held multiple leadership positions at Amgen Inc. from September 1997 to January 2005, including General Manager, Nephrology Europe. Mr. Munshi also cofounded Oxeia Biopharmaceuticals, Inc., a clinical-stage biotechnology company, in August 2014. In July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Munshi serves on the board of directors of the following publicly traded companies: Zura Bio Inc. (Nasdaq: ZURA) since March 2023 and Inhibikase Therapeutics, Inc. (Nasdaq: IKT) since October 2024, and previously served on the board of Arena Pharmaceuticals, Inc., a publicly traded company that was acquired by Pfizer Inc. in March 2022. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University. - AmitD.Munshi自2020年起担任我们的董事会主席。Munshi先生目前自2016年5月起担任生物制药公司ArenaPharmaceuticals，Inc.的总裁兼首席执行官。在此之前，Munshi先生于2012年5月至2016年5月担任生物制药公司EPIRUSBiopharmaceuticals，Inc.的总裁兼首席执行官。他曾担任Percivia公司（生物技术公司，后被JNJ公司收购）的总裁兼首席执行官（2011年4月至2012年5月）。在其职业生涯早期，Munshi先生于2005年8月至2011年1月共同创立并担任KytheraBiopharmaceuticals，Inc.（后被AGN收购）的首席商务官，并于1997年9月至2005年1月在安进公司担任多个领导职位，包括肾脏学欧洲总经理。Munshi先生还于2014年8月共同创立了Oxeia Biopharmaceuticals，Inc.，这是一家临床阶段的生物技术公司。Munshi先生目前在Pulmatrix，Inc.董事会任职。纳斯达克股票代码:PULM。2016年7月，Epirus向美国马萨诸塞州破产法院提交了自愿的第7章请愿书。Munshi先生拥有加州大学河滨分校（University of California，Riverside）的经济学学士学位和历史学学士学位，以及克莱蒙特研究生大学彼得·德鲁克管理学院（Peter F.Drucker School of Management at Claremont Graduate University）的工商管理硕士学位。
- Amit D. Munshi,served as President, Chief Executive Officer and board member of ORNA Therapeutics from May 2024 until March 2025 and, prior to that he served in the same roles at ReNAgade Therapeutics, a private biotechnology company that was acquired by ORNA Therapeutics, from May 2023 until May 2024. Prior to that, Mr. Munshi served as President, Chief Executive Officer and a director of Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company, from May 2016 until its acquisition by Pfizer Inc. in March 2022. Mr. Munshi served as President and Chief Executive Officer and a director of Epirus Biopharmaceuticals, Inc. ("Epirus") (Nasdaq: EPRS), a biopharmaceutical company, from May 2012 to May 2016. He served as President and Chief Executive Officer of Percivia LLC, a biotechnology company later acquired by Johnson & Johnson, from April 2011 to May 2012. Earlier in his career, Mr. Munshi co-founded and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., later acquired by Allergan plc, from August 2005 to January 2011, and held multiple leadership positions at Amgen Inc. from September 1997 to January 2005, including General Manager, Nephrology Europe. Mr. Munshi also cofounded Oxeia Biopharmaceuticals, Inc., a clinical-stage biotechnology company, in August 2014. In July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Mr. Munshi serves on the board of directors of the following publicly traded companies: Zura Bio Inc. (Nasdaq: ZURA) since March 2023 and Inhibikase Therapeutics, Inc. (Nasdaq: IKT) since October 2024, and previously served on the board of Arena Pharmaceuticals, Inc., a publicly traded company that was acquired by Pfizer Inc. in March 2022. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University.
- Hans T. Schambye
-
Hans T.Schambye自2011年11月以来一直担任Galecto Group的首席执行官，包括自2020年以来担任Galecto，Inc.的首席执行官，自2020年以来担任我们的董事会成员。在加入我们之前，Schambye博士从2006年9月到2009年11月担任Recepticon A/S（一家丹麦生物技术公司）的首席执行官。任职Recepticon A/S公司之前，Schambye博士曾任职Gastrotech Pharma A/S公司（丹麦生物技术公司），在那里他曾担任越来越重要的职务，包括高级副总裁，研发（从2004年3月到2005年2月），以及首席执行官（从2005年2月到2006年8月）。在他职业生涯的早期，Schambye博士担任Maxygen（一家美国生物技术公司）的生物学和药理学总监以及投资组合管理主管。Schambye博士联合创立了多家生物技术公司，包括丹麦生物技术公司Profect Pharma A/S，该公司于2000年被Maxygen收购。Schambye博士拥有欧登塞大学（Odense University）的医学博士学位和哥本哈根大学（Copenhagen University）的医疗保健与医学博士学位。
Hans T. Schambye,served as the Chief Executive Officer of ReceptIcon A/S, a Danish biotechnology company, from September 2006 to November 2009. Before ReceptIcon A/S, Dr. Schambye worked at Gastrotech Pharma A/S, a Danish biotechnology company, where he served in increasing roles of responsibility, including Senior Vice President, Research & Development from March 2004 to February 2005 and as Chief Executive Officer from February 2005 to August 2006. Earlier in his career, Dr. Schambye served as Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a U.S. biotechnology company. Dr. Schambye has co-founded several biotechnology companies, including ProFound Pharma A/S, a Danish biotechnology company, which was acquired by Maxygen in 2000. Dr. Schambye holds an M.D. from Odense University and a Ph.D. in Health Care and Medicine from Copenhagen University. - Hans T.Schambye自2011年11月以来一直担任Galecto Group的首席执行官，包括自2020年以来担任Galecto，Inc.的首席执行官，自2020年以来担任我们的董事会成员。在加入我们之前，Schambye博士从2006年9月到2009年11月担任Recepticon A/S（一家丹麦生物技术公司）的首席执行官。任职Recepticon A/S公司之前，Schambye博士曾任职Gastrotech Pharma A/S公司（丹麦生物技术公司），在那里他曾担任越来越重要的职务，包括高级副总裁，研发（从2004年3月到2005年2月），以及首席执行官（从2005年2月到2006年8月）。在他职业生涯的早期，Schambye博士担任Maxygen（一家美国生物技术公司）的生物学和药理学总监以及投资组合管理主管。Schambye博士联合创立了多家生物技术公司，包括丹麦生物技术公司Profect Pharma A/S，该公司于2000年被Maxygen收购。Schambye博士拥有欧登塞大学（Odense University）的医学博士学位和哥本哈根大学（Copenhagen University）的医疗保健与医学博士学位。
- Hans T. Schambye,served as the Chief Executive Officer of ReceptIcon A/S, a Danish biotechnology company, from September 2006 to November 2009. Before ReceptIcon A/S, Dr. Schambye worked at Gastrotech Pharma A/S, a Danish biotechnology company, where he served in increasing roles of responsibility, including Senior Vice President, Research & Development from March 2004 to February 2005 and as Chief Executive Officer from February 2005 to August 2006. Earlier in his career, Dr. Schambye served as Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a U.S. biotechnology company. Dr. Schambye has co-founded several biotechnology companies, including ProFound Pharma A/S, a Danish biotechnology company, which was acquired by Maxygen in 2000. Dr. Schambye holds an M.D. from Odense University and a Ph.D. in Health Care and Medicine from Copenhagen University.
- Chris Cain
-
Chris Cain自2020年7月起担任我们的董事会成员，是医疗保健投资基金Fairmount Funds Management LLC“Fairmount Funds”的指定人。Cain博士自2020年4月以来一直担任Fairmount Funds的研究总监。从2019年2月至2020年2月，Cain博士担任专注于生物治疗的风险投资基金Samsara Biocapital的副总裁。在担任该职位之前，该隐博士于2016年7月至2019年1月在专注于生命科学的风险投资基金Apple Tree Partners任职，最近担任高级合伙人。Cain博士于2014年11月至2016年5月担任投资管理公司RA Capital Management的合伙人。在此之前，Cain博士于2010年6月至2014年10月在BioCentury Publications任职，最近担任副主编。他在加州大学圣巴巴拉分校获得文学士学位，在加州大学旧金山分校获得生物化学和分子生物学博士学位。
Chris Cain has served as a member of Board since July 2024. Dr. Cain has served as Director of Research at Fairmount Funds Management LLC, a healthcare investment firm, since April 2020. Prior to Fairmount, Dr. Cain served in vario positions, his most recent being Vice President, at healthcare funds, including Samsara BioCapital, LP, a biotherapeutics foced venture capital fund, from February 2019 to February 2020, Apple Tree Partners, a life sciences foced venture capital fund, from 2016 to January 2019, and, before that, RA Capital Management, an investment management company, where he invested in both public and emerging private biotechnology companies. Previoly, Dr. Cain was a writer and editor at BioCentury Publications. He currently serves as a member of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT), Viridian Therapeutics Inc. (Nasdaq: VRDN) and Galecto Inc. (Nasdaq: GLTO). He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco. - Chris Cain自2020年7月起担任我们的董事会成员，是医疗保健投资基金Fairmount Funds Management LLC“Fairmount Funds”的指定人。Cain博士自2020年4月以来一直担任Fairmount Funds的研究总监。从2019年2月至2020年2月，Cain博士担任专注于生物治疗的风险投资基金Samsara Biocapital的副总裁。在担任该职位之前，该隐博士于2016年7月至2019年1月在专注于生命科学的风险投资基金Apple Tree Partners任职，最近担任高级合伙人。Cain博士于2014年11月至2016年5月担任投资管理公司RA Capital Management的合伙人。在此之前，Cain博士于2010年6月至2014年10月在BioCentury Publications任职，最近担任副主编。他在加州大学圣巴巴拉分校获得文学士学位，在加州大学旧金山分校获得生物化学和分子生物学博士学位。
- Chris Cain has served as a member of Board since July 2024. Dr. Cain has served as Director of Research at Fairmount Funds Management LLC, a healthcare investment firm, since April 2020. Prior to Fairmount, Dr. Cain served in vario positions, his most recent being Vice President, at healthcare funds, including Samsara BioCapital, LP, a biotherapeutics foced venture capital fund, from February 2019 to February 2020, Apple Tree Partners, a life sciences foced venture capital fund, from 2016 to January 2019, and, before that, RA Capital Management, an investment management company, where he invested in both public and emerging private biotechnology companies. Previoly, Dr. Cain was a writer and editor at BioCentury Publications. He currently serves as a member of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT), Viridian Therapeutics Inc. (Nasdaq: VRDN) and Galecto Inc. (Nasdaq: GLTO). He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.
- Peter Harwin
-
Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
Peter Harwin has served as a member of our Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University. - Peter Harwin自2020年7月以来一直担任我们的董事会成员，是Fairmount Funds的指定人。他目前是Fairmount Funds（他于2016年4月联合创立的医疗保健投资基金）的管理成员。在加入Fairmount Funds之前，Harwin先生曾担任Boxer Capital，LLC（Tavistock Group的一部分，位于圣地亚哥）的投资团队成员，最近担任该团队的高级成员。除了在Fairmount Funds的职责外，Harwin先生还担任Dianthus Therapeutics，Inc.的战略顾问。Harwin先生还担任Viridian Therapeutics，Inc.的董事会成员。纳斯达克:VRDN。Harwin先生在埃默里大学获得了学士学位。
- Peter Harwin has served as a member of our Board since October 2020. Mr. Harwin is currently a managing member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount, Mr. Harwin served as a member of the investment team at Boxer Capital, LLC, a private biotechnology investment fund as part of the Tavistock Group, based in San Diego, most recently serving as a senior member of the team. In addition to his responsibilities at Fairmount, Mr. Harwin serves as a strategic advisor to biotechnology companies Quellis Biosciences Inc. and Dianthus Therapeutics, Inc. Mr. Harwin currently serves as Chairman of the Board for Cogent Biosciences, Inc., a publicly-traded biopharmaceutical company. He received his Bachelor of Business Administration degree from Emory University.
- Peter Harwin
-
Peter Harwin是Fairmount Funds Management LLC（“Fairmount”）的管理成员，该公司是他于2016年4月与人共同创立的医疗保健投资公司。在加入Fairmount之前，他是Boxer Capital，LLC投资团队的成员，该投资基金是Tavistock集团的一部分，总部位于加利福尼亚州圣地亚哥。Harwin先生还担任Cogent Biosciences, Inc.（纳斯达克：COGT）和Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会主席，并且是Apogee Therapeutics，Inc.（纳斯达克：APGE）、Spyre Therapeutics，Inc.（纳斯达克：SYRE）和Oruka Therapeutics，Inc.（纳斯达克：ORKA）的董事会成员。他获得了埃默里大学的学士学位。
Peter Harwin,is a Managing Member at Fairmount Funds Management LLC ("Fairmount"), a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, he was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego, California. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and Crescent Biopharma, Inc. (Nasdaq: CBIO) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE) and Oruka Therapeutics, Inc. (Nasdaq: ORKA). He received a B.B.A. from Emory University. - Peter Harwin是Fairmount Funds Management LLC（“Fairmount”）的管理成员，该公司是他于2016年4月与人共同创立的医疗保健投资公司。在加入Fairmount之前，他是Boxer Capital，LLC投资团队的成员，该投资基金是Tavistock集团的一部分，总部位于加利福尼亚州圣地亚哥。Harwin先生还担任Cogent Biosciences, Inc.（纳斯达克：COGT）和Crescent Biopharma，Inc.（纳斯达克：CBIO）的董事会主席，并且是Apogee Therapeutics，Inc.（纳斯达克：APGE）、Spyre Therapeutics，Inc.（纳斯达克：SYRE）和Oruka Therapeutics，Inc.（纳斯达克：ORKA）的董事会成员。他获得了埃默里大学的学士学位。
- Peter Harwin,is a Managing Member at Fairmount Funds Management LLC ("Fairmount"), a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, he was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego, California. Mr. Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and Crescent Biopharma, Inc. (Nasdaq: CBIO) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE) and Oruka Therapeutics, Inc. (Nasdaq: ORKA). He received a B.B.A. from Emory University.
- Chris Cain
-
Chris Cain，是Fairmount的研究主管。在2020年4月加入Fairmount之前，Cain博士曾在Samsara BioCapital、Apple Tree Partners和RA Capital Management的医疗保健基金担任多个职位，在那里他投资了上市和新兴的私营生物技术公司。凯恩博士还曾在BioCentury Publications担任作家和编辑。他还担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）、Cogent Biosciences, Inc.（纳斯达克：COGT）和Jade Biosciences，Inc.（纳斯达克：JBIO）的董事。凯恩博士获得了加州大学圣巴巴拉分校的学士学位和加州大学旧金山分校的生物化学和分子生物学博士学位。
Chris Cain,is the Director of Research at Fairmount. Prior to joining Fairmount in April 2020, Dr. Cain served in various positions at the healthcare funds at Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Dr. Cain has also served as a writer and editor at BioCentury Publications. He also serves as a director of Viridian Therapeutics, Inc. (Nasdaq: VRDN), Cogent Biosciences, Inc. (Nasdaq: COGT) and Jade Biosciences, Inc. (Nasdaq: JBIO). Dr. Cain received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco. - Chris Cain，是Fairmount的研究主管。在2020年4月加入Fairmount之前，Cain博士曾在Samsara BioCapital、Apple Tree Partners和RA Capital Management的医疗保健基金担任多个职位，在那里他投资了上市和新兴的私营生物技术公司。凯恩博士还曾在BioCentury Publications担任作家和编辑。他还担任Viridian Therapeutics, Inc.（纳斯达克：VRDN）、Cogent Biosciences, Inc.（纳斯达克：COGT）和Jade Biosciences，Inc.（纳斯达克：JBIO）的董事。凯恩博士获得了加州大学圣巴巴拉分校的学士学位和加州大学旧金山分校的生物化学和分子生物学博士学位。
- Chris Cain,is the Director of Research at Fairmount. Prior to joining Fairmount in April 2020, Dr. Cain served in various positions at the healthcare funds at Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Dr. Cain has also served as a writer and editor at BioCentury Publications. He also serves as a director of Viridian Therapeutics, Inc. (Nasdaq: VRDN), Cogent Biosciences, Inc. (Nasdaq: COGT) and Jade Biosciences, Inc. (Nasdaq: JBIO). Dr. Cain received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.
- Julianne Bruno
-
Julianne Bruno是Fairmount的成长合伙人，她自2025年5月以来一直担任该职位。在加入Fairmount之前，她是CRISPR Therapeutics AG（纳斯达克：CRSP）（“CRISPR”）领导团队的关键成员。在CRISPR的六年任期内，她曾担任多个血液学和肿瘤学项目的项目负责人，之后于2024年5月担任首席运营官，直至2025年4月。在这些角色中，她监督了卡斯盖维的发展并帮助公司运营模式成熟。布鲁诺女士还曾在麦肯锡公司担任生命科学实践的领导者。她获得了普林斯顿大学的A.B.和宾夕法尼亚大学沃顿商学院的MBA学位。
Julianne Bruno,is a Growth Partner at Fairmount, a position she has held since May 2025. Prior to joining Fairmount, she was a pivotal member of the CRISPR Therapeutics AG (Nasdaq: CRSP) ("CRISPR") leadership team. During her six-year tenure with CRISPR, she served as the Program Leader across multiple hematology and oncology programs before taking on the role of Chief Operating Officer in May 2024 until April 2025. In these roles, she oversaw the development of Casgevy and helped mature the operating model of the company. Ms. Bruno has also worked as a leader in the life sciences practice at McKinsey & Co. She received her A.B. from Princeton University and an MBA from the Wharton School, University of Pennsylvania. - Julianne Bruno是Fairmount的成长合伙人，她自2025年5月以来一直担任该职位。在加入Fairmount之前，她是CRISPR Therapeutics AG（纳斯达克：CRSP）（“CRISPR”）领导团队的关键成员。在CRISPR的六年任期内，她曾担任多个血液学和肿瘤学项目的项目负责人，之后于2024年5月担任首席运营官，直至2025年4月。在这些角色中，她监督了卡斯盖维的发展并帮助公司运营模式成熟。布鲁诺女士还曾在麦肯锡公司担任生命科学实践的领导者。她获得了普林斯顿大学的A.B.和宾夕法尼亚大学沃顿商学院的MBA学位。
- Julianne Bruno,is a Growth Partner at Fairmount, a position she has held since May 2025. Prior to joining Fairmount, she was a pivotal member of the CRISPR Therapeutics AG (Nasdaq: CRSP) ("CRISPR") leadership team. During her six-year tenure with CRISPR, she served as the Program Leader across multiple hematology and oncology programs before taking on the role of Chief Operating Officer in May 2024 until April 2025. In these roles, she oversaw the development of Casgevy and helped mature the operating model of the company. Ms. Bruno has also worked as a leader in the life sciences practice at McKinsey & Co. She received her A.B. from Princeton University and an MBA from the Wharton School, University of Pennsylvania.
- Carl Goldfischer
-
Carl Goldfischer 自2004年7月起，他担任本公司董事，目前担任海湾城市资本的投资合伙人兼总经理，是公司董事会及执行委员会成员，并自2000年12月起，他的背景包括广泛的公共和私人投资和交易工作，以及临床试验开发知识。加盟江湾城投资之前，直到2000年中期间。他一直担任imclone股份有限公司的财务总监，其是一家上市生物技术公司，专注于开发治疗肿瘤的产品，在那里他负责财务运作和战略规划。他同时担任多家私人公司的董事和审计委员。
Carl Goldfischer has served as a member of our board of directors since January 2016. Dr. Goldfischer has served as an Investment Partner, Managing Director, member of the board of directors and member of the executive committee of Bay City Capital LLC, or Bay City Capital, a life sciences investment firm, since January 2000. Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer and VP of Finance and Strategic Planning of ImClone Systems Inc., a biopharmaceutical company. Dr. Goldfischer has served on the board of directors of Epizyme, Inc., a public biopharmaceutical company, since September 2009. He has previously served on the board of directors of EnteroMedics Inc., now ReShape Lifesciences Inc., a public medical device company, from 2004 to September 2017 MAP Pharmaceuticals, Inc., a biopharmaceutical company, from 2004 to 2011 and Poniard Pharmaceuticals, Inc., a public biopharmaceutical company, from 2000 to 2012. Dr. Goldfischer received his B.A. in Liberal Arts from Sarah Lawrence College and his M.D. with honors in scientific research from Albert Einstein College of Medicine at Yeshiva University. - Carl Goldfischer 自2004年7月起，他担任本公司董事，目前担任海湾城市资本的投资合伙人兼总经理，是公司董事会及执行委员会成员，并自2000年12月起，他的背景包括广泛的公共和私人投资和交易工作，以及临床试验开发知识。加盟江湾城投资之前，直到2000年中期间。他一直担任imclone股份有限公司的财务总监，其是一家上市生物技术公司，专注于开发治疗肿瘤的产品，在那里他负责财务运作和战略规划。他同时担任多家私人公司的董事和审计委员。
- Carl Goldfischer has served as a member of our board of directors since January 2016. Dr. Goldfischer has served as an Investment Partner, Managing Director, member of the board of directors and member of the executive committee of Bay City Capital LLC, or Bay City Capital, a life sciences investment firm, since January 2000. Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer and VP of Finance and Strategic Planning of ImClone Systems Inc., a biopharmaceutical company. Dr. Goldfischer has served on the board of directors of Epizyme, Inc., a public biopharmaceutical company, since September 2009. He has previously served on the board of directors of EnteroMedics Inc., now ReShape Lifesciences Inc., a public medical device company, from 2004 to September 2017 MAP Pharmaceuticals, Inc., a biopharmaceutical company, from 2004 to 2011 and Poniard Pharmaceuticals, Inc., a public biopharmaceutical company, from 2000 to 2012. Dr. Goldfischer received his B.A. in Liberal Arts from Sarah Lawrence College and his M.D. with honors in scientific research from Albert Einstein College of Medicine at Yeshiva University.
高管简历
中英对照 | 中文 | 英文- Hans T. Schambye
Hans T.Schambye自2011年11月以来一直担任Galecto Group的首席执行官，包括自2020年以来担任Galecto，Inc.的首席执行官，自2020年以来担任我们的董事会成员。在加入我们之前，Schambye博士从2006年9月到2009年11月担任Recepticon A/S（一家丹麦生物技术公司）的首席执行官。任职Recepticon A/S公司之前，Schambye博士曾任职Gastrotech Pharma A/S公司（丹麦生物技术公司），在那里他曾担任越来越重要的职务，包括高级副总裁，研发（从2004年3月到2005年2月），以及首席执行官（从2005年2月到2006年8月）。在他职业生涯的早期，Schambye博士担任Maxygen（一家美国生物技术公司）的生物学和药理学总监以及投资组合管理主管。Schambye博士联合创立了多家生物技术公司，包括丹麦生物技术公司Profect Pharma A/S，该公司于2000年被Maxygen收购。Schambye博士拥有欧登塞大学（Odense University）的医学博士学位和哥本哈根大学（Copenhagen University）的医疗保健与医学博士学位。
Hans T. Schambye,served as the Chief Executive Officer of ReceptIcon A/S, a Danish biotechnology company, from September 2006 to November 2009. Before ReceptIcon A/S, Dr. Schambye worked at Gastrotech Pharma A/S, a Danish biotechnology company, where he served in increasing roles of responsibility, including Senior Vice President, Research & Development from March 2004 to February 2005 and as Chief Executive Officer from February 2005 to August 2006. Earlier in his career, Dr. Schambye served as Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a U.S. biotechnology company. Dr. Schambye has co-founded several biotechnology companies, including ProFound Pharma A/S, a Danish biotechnology company, which was acquired by Maxygen in 2000. Dr. Schambye holds an M.D. from Odense University and a Ph.D. in Health Care and Medicine from Copenhagen University.- Hans T.Schambye自2011年11月以来一直担任Galecto Group的首席执行官，包括自2020年以来担任Galecto，Inc.的首席执行官，自2020年以来担任我们的董事会成员。在加入我们之前，Schambye博士从2006年9月到2009年11月担任Recepticon A/S（一家丹麦生物技术公司）的首席执行官。任职Recepticon A/S公司之前，Schambye博士曾任职Gastrotech Pharma A/S公司（丹麦生物技术公司），在那里他曾担任越来越重要的职务，包括高级副总裁，研发（从2004年3月到2005年2月），以及首席执行官（从2005年2月到2006年8月）。在他职业生涯的早期，Schambye博士担任Maxygen（一家美国生物技术公司）的生物学和药理学总监以及投资组合管理主管。Schambye博士联合创立了多家生物技术公司，包括丹麦生物技术公司Profect Pharma A/S，该公司于2000年被Maxygen收购。Schambye博士拥有欧登塞大学（Odense University）的医学博士学位和哥本哈根大学（Copenhagen University）的医疗保健与医学博士学位。
- Hans T. Schambye,served as the Chief Executive Officer of ReceptIcon A/S, a Danish biotechnology company, from September 2006 to November 2009. Before ReceptIcon A/S, Dr. Schambye worked at Gastrotech Pharma A/S, a Danish biotechnology company, where he served in increasing roles of responsibility, including Senior Vice President, Research & Development from March 2004 to February 2005 and as Chief Executive Officer from February 2005 to August 2006. Earlier in his career, Dr. Schambye served as Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a U.S. biotechnology company. Dr. Schambye has co-founded several biotechnology companies, including ProFound Pharma A/S, a Danish biotechnology company, which was acquired by Maxygen in 2000. Dr. Schambye holds an M.D. from Odense University and a Ph.D. in Health Care and Medicine from Copenhagen University.
- Matthew Kronmiller
Matthew Kronmiller，自2022年10月起担任Bridge Medicines首席执行官。2011年至2024年10月，他还在贝城资本担任副总裁，负责开发财务分析、开展研究，并支持生物制药、诊断、医疗保健 IT和医疗器械领域当前和潜在的投资。在加入Bay City Capital之前，Kronmiller先生是美银美林医疗保健集团的投资银行分析师，为各种公共和私人医疗保健客户的多项并购和公司融资交易提供咨询服务。Kronmiller先生在宾夕法尼亚州立大学获得金融学学士学位。
Matthew Kronmiller,served as the Chief Executive Officer of Bridge Medicines since October 2022. He also served as Vice President at Bay City Capital from 2011 to October 2024, where he was responsible for developing financial analyses, conducting research, and supporting current and potential investments in the areas of biopharma, diagnostics, healthcare IT, and medical devices. Prior to joining Bay City Capital, Mr. Kronmiller was an Investment Banking Analyst in the Healthcare group at Bank of America Merrill Lynch, where he advised on a number of M&A and corporate finance transactions for a variety of public and private healthcare clients. Mr. Kronmiller received his BS in Finance from Pennsylvania State University.- Matthew Kronmiller，自2022年10月起担任Bridge Medicines首席执行官。2011年至2024年10月，他还在贝城资本担任副总裁，负责开发财务分析、开展研究，并支持生物制药、诊断、医疗保健 IT和医疗器械领域当前和潜在的投资。在加入Bay City Capital之前，Kronmiller先生是美银美林医疗保健集团的投资银行分析师，为各种公共和私人医疗保健客户的多项并购和公司融资交易提供咨询服务。Kronmiller先生在宾夕法尼亚州立大学获得金融学学士学位。
- Matthew Kronmiller,served as the Chief Executive Officer of Bridge Medicines since October 2022. He also served as Vice President at Bay City Capital from 2011 to October 2024, where he was responsible for developing financial analyses, conducting research, and supporting current and potential investments in the areas of biopharma, diagnostics, healthcare IT, and medical devices. Prior to joining Bay City Capital, Mr. Kronmiller was an Investment Banking Analyst in the Healthcare group at Bank of America Merrill Lynch, where he advised on a number of M&A and corporate finance transactions for a variety of public and private healthcare clients. Mr. Kronmiller received his BS in Finance from Pennsylvania State University.
- Lori Firmani
Lori Firmani，自2020年4月起担任Spring Bank Pharmaceuticals，Inc.的首席财务官，直至该公司于2020年11月被收购，在此之前，他于2016年1月至2020年4月期间担任越来越重要的财务职务。Firmani女士是马萨诸塞州联邦的注册会计师，拥有巴布森学院的MBA学位和纽约州立大学Geneseo的会计学学士学位。
Lori Firmani,served as Chief Financial Officer of Spring Bank Pharmaceuticals, Inc. from April 2020 until its acquisition in November 2020, and prior to that served in financial roles of increasing responsibility from January 2016 to April 2020. Ms. Firmani is a certified public accountant in the Commonwealth of Massachusetts and holds an MBA from Babson College and a BS in Accounting from the State University of New York at Geneseo.- Lori Firmani，自2020年4月起担任Spring Bank Pharmaceuticals，Inc.的首席财务官，直至该公司于2020年11月被收购，在此之前，他于2016年1月至2020年4月期间担任越来越重要的财务职务。Firmani女士是马萨诸塞州联邦的注册会计师，拥有巴布森学院的MBA学位和纽约州立大学Geneseo的会计学学士学位。
- Lori Firmani,served as Chief Financial Officer of Spring Bank Pharmaceuticals, Inc. from April 2020 until its acquisition in November 2020, and prior to that served in financial roles of increasing responsibility from January 2016 to April 2020. Ms. Firmani is a certified public accountant in the Commonwealth of Massachusetts and holds an MBA from Babson College and a BS in Accounting from the State University of New York at Geneseo.
- Garrett Winslow
Garrett Winslow，于2017年1月至2020年11月担任生物制药公司Spring Bank Pharmaceuticals, Inc.的总法律顾问和公司秘书。在此之前，Winslow先生是Mintz、Levin、Cohn、Ferris、Glovsky和Popeo，P.C.波士顿办事处企业和证券组的成员。Winslow先生在波士顿大学法学院获得税务硕士学位，在萨福克大学法学院获得法学博士学位，在华盛顿大学获得工商管理学士学位。
Garrett Winslow,served as the General Counsel and Corporate Secretary of Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company, from January 2017 to November 2020. Prior to that, Mr. Winslow was a member in the Corporate and Securities group at the Boston office of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. Mr. Winslow received his Masters in Taxation from Boston University Law School, J.D. from Suffolk University Law School and B.A. degree in Business Administration from the University of Washington.- Garrett Winslow，于2017年1月至2020年11月担任生物制药公司Spring Bank Pharmaceuticals, Inc.的总法律顾问和公司秘书。在此之前，Winslow先生是Mintz、Levin、Cohn、Ferris、Glovsky和Popeo，P.C.波士顿办事处企业和证券组的成员。Winslow先生在波士顿大学法学院获得税务硕士学位，在萨福克大学法学院获得法学博士学位，在华盛顿大学获得工商管理学士学位。
- Garrett Winslow,served as the General Counsel and Corporate Secretary of Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company, from January 2017 to November 2020. Prior to that, Mr. Winslow was a member in the Corporate and Securities group at the Boston office of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. Mr. Winslow received his Masters in Taxation from Boston University Law School, J.D. from Suffolk University Law School and B.A. degree in Business Administration from the University of Washington.